STN1013400

STN1013400 is a selective muscarinic M2 receptor antagonist developed as an ophthalmic small molecule therapy to slow the progression of juvenile myopia. Unlike nonselective agents such as atropine, which can cause side effects like mydriasis by acting on multiple muscarinic receptor subtypes, STN1013400 (active ingredient: AFDX0250BS) exhibits divergent affinities for the M2 and M3 receptors. This selectivity is expected to provide therapeutic efficacy in inhibiting myopia progression while reducing unwanted side effects such as pupil dilation. The drug is being developed by Santen Pharmaceutical and has completed Phase 1 trials in healthy volunteers in Japan and China, with ongoing or planned Phase 2a studies for myopia[1][2][4][5].

Other names

STN1013400STN-1013400STN 1013400AFDX0250BSAFDX-0250BSAFDX 0250BS